Tetracycline use in the community may promote decreased susceptibility to quinolones in Escherichia coli isolates

Eur J Clin Microbiol Infect Dis. 2018 Feb;37(2):271-276. doi: 10.1007/s10096-017-3127-0. Epub 2017 Oct 26.

Abstract

We previously found that the hospital use of tetracyclines is associated with quinolone resistance in hospital isolates of Enterobacteriaceae. Tetracyclines are heavily used in the community. Our aim was to assess whether their use in the community favors quinolone resistance in community isolates of Escherichia coli. Monthly data of community antibiotics use and E. coli quinolone resistance in a 1.3 million inhabitant French area were obtained from 2009 to 2014, and were analyzed with autoregressive integrated moving average (ARIMA) models. Quinolone use decreased from 10.1% of the total antibiotic use in 2009 to 9.3% in 2014 (trend, - 0.016; p-value < 0.0001), while tetracycline use increased from 16.5% in 2009 to 17.1% in 2014 (trend, 0.016; p < 0.0001). The mean (95% confidence interval) monthly proportions of isolates that were non-susceptible to nalidixic acid and ciprofloxacin were 14.8% (14.2%-15.5%) and 9.5% (8.8%-10.1%), respectively, with no significant temporal trend. After adjusting on quinolone use, tetracycline use in the preceding month was significantly associated with nalidixic acid non-susceptibility (estimate [SD], 0.01 [0.007]; p-value, 0.04), but not with ciprofloxacin non-susceptibility (estimate [SD], 0.01 [0.009]; p-value, 0.23). Tetracycline use in the community may promote quinolone non-susceptibility in E. coli. Decreasing both tetracycline and quinolone use may be necessary to fight against the worldwide growth of quinolone resistance.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use*
  • Ciprofloxacin / therapeutic use*
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / microbiology
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Escherichia coli / drug effects*
  • Escherichia coli / isolation & purification
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / microbiology
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Nalidixic Acid / therapeutic use*
  • Retrospective Studies
  • Tetracycline / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Nalidixic Acid
  • Ciprofloxacin
  • Tetracycline